Annual Cash & Cash Equivalents
$97.25 M
-$89.48 M-47.92%
December 31, 2024
Summary
- As of March 12, 2025, PTGX annual cash & cash equivalents is $97.25 million, with the most recent change of -$89.48 million (-47.92%) on December 31, 2024.
- During the last 3 years, PTGX annual cash & cash equivalents has fallen by -$26.42 million (-21.36%).
- PTGX annual cash & cash equivalents is now -47.92% below its all-time high of $186.73 million, reached on December 31, 2023.
Performance
PTGX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$97.25 M
-$33.87 M-25.83%
December 31, 2024
Summary
- As of March 12, 2025, PTGX quarterly cash and cash equivalents is $97.25 million, with the most recent change of -$33.87 million (-25.83%) on December 31, 2024.
- Over the past year, PTGX quarterly cash and cash equivalents has dropped by -$33.87 million (-25.83%).
- PTGX quarterly cash and cash equivalents is now -72.66% below its all-time high of $355.64 million, reached on June 30, 2024.
Performance
PTGX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PTGX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -47.9% | -25.8% |
| 3 y3 years | -21.4% | -25.8% |
| 5 y5 years | +194.6% | -25.8% |
PTGX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -47.9% | at low | -72.7% | at low |
| 5 y | 5-year | -47.9% | +194.6% | -72.7% | +194.6% |
| alltime | all time | -47.9% | +2298.3% | -72.7% | +2298.3% |
Protagonist Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $97.25 M(-47.9%) | $97.25 M(-25.8%) |
| Sep 2024 | - | $131.12 M(-63.1%) |
| Jun 2024 | - | $355.64 M(+106.1%) |
| Mar 2024 | - | $172.57 M(-7.6%) |
| Dec 2023 | $186.73 M(+48.5%) | $186.73 M(-19.0%) |
| Sep 2023 | - | $230.53 M(-2.1%) |
| Jun 2023 | - | $235.38 M(+84.3%) |
| Mar 2023 | - | $127.69 M(+1.5%) |
| Dec 2022 | $125.74 M(+1.7%) | $125.74 M(-17.7%) |
| Sep 2022 | - | $152.82 M(+27.1%) |
| Jun 2022 | - | $120.24 M(+22.1%) |
| Mar 2022 | - | $98.48 M(-20.4%) |
| Dec 2021 | $123.67 M(+5.4%) | $123.67 M(+2.6%) |
| Sep 2021 | - | $120.54 M(-37.4%) |
| Jun 2021 | - | $192.41 M(+131.8%) |
| Mar 2021 | - | $83.00 M(-29.3%) |
| Dec 2020 | $117.36 M | $117.36 M(+40.3%) |
| Sep 2020 | - | $83.63 M(-42.8%) |
| Jun 2020 | - | $146.24 M(+142.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $60.22 M(+82.4%) |
| Dec 2019 | $33.01 M(-59.9%) | $33.01 M(-34.2%) |
| Sep 2019 | - | $50.20 M(-29.4%) |
| Jun 2019 | - | $71.14 M(+1.5%) |
| Mar 2019 | - | $70.08 M(-14.8%) |
| Dec 2018 | $82.23 M(-22.4%) | $82.23 M(-5.9%) |
| Sep 2018 | - | $87.43 M(+36.9%) |
| Jun 2018 | - | $63.86 M(-8.2%) |
| Mar 2018 | - | $69.58 M(-34.4%) |
| Dec 2017 | $106.03 M(+402.9%) | $106.03 M(+110.4%) |
| Sep 2017 | - | $50.40 M(+386.2%) |
| Jun 2017 | - | $10.37 M(+8.9%) |
| Mar 2017 | - | $9.52 M(-54.9%) |
| Dec 2016 | $21.08 M(+420.0%) | $21.08 M(-78.0%) |
| Sep 2016 | - | $96.02 M(+597.4%) |
| Jun 2016 | - | $13.77 M(-51.9%) |
| Mar 2016 | - | $28.63 M(+606.0%) |
| Dec 2015 | $4.05 M(-56.5%) | $4.05 M |
| Dec 2014 | $9.32 M | - |
FAQ
- What is Protagonist Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual cash & cash equivalents year-on-year change?
- What is Protagonist Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Protagonist Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PTGX is $97.25 M
What is the all time high annual cash & cash equivalents for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash & cash equivalents is $186.73 M
What is Protagonist Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, PTGX annual cash & cash equivalents has changed by -$89.48 M (-47.92%)
What is Protagonist Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PTGX is $97.25 M
What is the all time high quarterly cash and cash equivalents for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash and cash equivalents is $355.64 M
What is Protagonist Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, PTGX quarterly cash and cash equivalents has changed by -$33.87 M (-25.83%)